381 related articles for article (PubMed ID: 32748118)
1. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
[TBL] [Abstract][Full Text] [Related]
2. Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients.
Vaitiekus D; Muckiene G; Vaitiekiene A; Maciuliene D; Vaiciuliene D; Ambrazeviciute G; Sereikaite L; Verikas D; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2020 Jun; 20(3):321-327. PubMed ID: 31782105
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity.
Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H
BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation.
Cascales A; Sánchez-Vega B; Navarro N; Pastor-Quirante F; Corral J; Vicente V; de la Peña FA
Int J Cardiol; 2012 Feb; 154(3):282-6. PubMed ID: 20974500
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
7. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
8. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
[TBL] [Abstract][Full Text] [Related]
9. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
10. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
11. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
[TBL] [Abstract][Full Text] [Related]
12. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
Guenancia C; Lefebvre A; Cardinale D; Yu AF; Ladoire S; Ghiringhelli F; Zeller M; Rochette L; Cottin Y; Vergely C
J Clin Oncol; 2016 Sep; 34(26):3157-65. PubMed ID: 27458291
[TBL] [Abstract][Full Text] [Related]
13. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis.
Mohamed AA; Elmancy LY; Abulola SM; Al-Qattan SA; Mohamed Ibrahim MI; Maayah ZH
Cardiovasc Toxicol; 2024 Jun; 24(6):563-575. PubMed ID: 38700665
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
17. Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
Vivenza D; Feola M; Garrone O; Monteverde M; Merlano M; Lo Nigro C
Int J Biol Markers; 2013 Dec; 28(4):e336-47. PubMed ID: 23999848
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for anthracycline-associated cardiotoxicity.
Reinbolt RE; Patel R; Pan X; Timmers CD; Pilarski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2016 May; 24(5):2173-2180. PubMed ID: 26563179
[TBL] [Abstract][Full Text] [Related]
19. Is there scope for better individualisation of anthracycline cancer chemotherapy?
Sallustio BC; Boddy AV
Br J Clin Pharmacol; 2021 Feb; 87(2):295-305. PubMed ID: 33118175
[TBL] [Abstract][Full Text] [Related]
20. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
